{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:53:00Z","timestamp":1774597980290,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018368","name":"UnitedHealth Group","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018368","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen Inc"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Exact Sciences"},{"DOI":"10.13039\/100006396","name":"Alexion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clovis"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Opioid use by patients with inflammatory bowel disease (IBD) has been associated with poorer health outcomes. This study describes socioeconomic characteristics; health utilization trends; and costs of patients with IBD and either no opioid prescriptions, or in 1 of 3 opioid duration categories based on Center for Disease Control guidelines: acute (0\u201330 days), moderate (31\u201390 days), or chronic (&amp;gt;90 days). We utilized the Cost of IBD Care Optum research database results for this study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Optum Research Database from years 2007 to 2016 including IBD patients with commercial or Medicare Advantage insurance in the United States was used. Additional inclusion criteria included continuous enrollment with medical and pharmacy benefit coverage for at least 24 months (12 months before and 12 months after the index date of IBD diagnosis). The association between costs and patient characteristics were assessed across a no opioid use group during this period and the 3 opioid duration groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 51,178 IBD patients, 33,229 (64.93%) were part of the no opioid use group, while 13,635 (26.64%) were in acute, 1698 (3.32%) were in moderate, and 2616 (5.11%) were in chronic use groups, as determined by pharmacy claims data. Patients in the chronic group were more likely to be white (75.38%) compared to all the other groups (no opioid use, acute, and moderate), have attained less education (only high school diploma), have had lower incomes, and have had Medicare instead of commercial insurance. Patients across all opioid prescription groups were more likely to have had diagnoses associated with pain in the prior year, with rates increasing by the length of opioid prescription (63.68%, 80.17%, and 86.11% for acute, moderate, and chronic groups). Compared to the no-use group, the acute group had more ambulatory (outpatient) visits, while the chronic group had fewer. Emergency department visits and inpatient hospitalizations were higher in all 3 opioid groups compared to the no opioid use group. Ambulatory, emergency department, inpatient, and total (medical + pharmacy) costs were higher in all 3 opioid groups, compared to the no opioid use group, even after adjusting for demographic and clinical patient characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Among patients with IBD, increasing opioid use was associated with higher healthcare resource utilization and, concomitantly, higher healthcare costs during this period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otab021","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T20:12:54Z","timestamp":1616098374000},"source":"Crossref","is-referenced-by-count":4,"title":["Opioid Use Associated With Higher Costs Among Patients With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-581X","authenticated-orcid":false,"given":"Eva M","family":"Szigethy","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Medicine, University of Pittsburgh , Pittsburgh, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Population Health Sciences, Weill Cornell Medical College , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orna G","family":"Ehrlich","sequence":"additional","affiliation":[{"name":"Research Department, Crohn\u2019s & Colitis Foundation , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caren A","family":"Heller","sequence":"additional","affiliation":[{"name":"Research Department, Crohn\u2019s & Colitis Foundation , New York, New York , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M","family":"Engel-Nitz","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research Department, Optum , Eden Prairie, Minnesota , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry","family":"Meadows","sequence":"additional","affiliation":[{"name":"Department of Government Programs, Medical Director, Government Programs, Geisinger Health Plan , Danville, Pennsylvania , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John I","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Michigan School of Medicine , Ann Arbor, Michigan , USA"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan , Ann Arbor, Michigan , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"2022111812273453100_CIT0001","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ajg.2012.260","article-title":"Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis","volume":"107","author":"Halpin","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0002","doi-asserted-by":"crossref","first-page":"e0156666","DOI":"10.1371\/journal.pone.0156666","article-title":"Pain in IBD patients: very frequent and frequently insufficiently taken into account","volume":"11","author":"Zeitz","year":"2016","journal-title":"PLoS One."},{"key":"2022111812273453100_CIT0003","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9270(01)04037-0","article-title":"Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Simr\u00e9n","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0004","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3748\/wjg.v16.i25.3168","article-title":"Impact of pain on health-related quality of life in patients with inflammatory bowel disease","volume":"16","author":"Schirbel","year":"2010","journal-title":"World J Gastroenterol."},{"key":"2022111812273453100_CIT0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med."},{"key":"2022111812273453100_CIT0006","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/ajg.2014.230","article-title":"The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis","volume":"109","author":"Targownik","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0007","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MIB.0000000000001017","article-title":"Prevalence and impact of inflammatory bowel disease-irritable bowel syndrome on patient-reported outcomes in CCFA partners","volume":"23","author":"Abdalla","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0008","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1046\/j.1440-1746.2001.02468.x","article-title":"Chronic narcotic use in inflammatory bowel disease patients: prevalence and clinical characteristics","volume":"16","author":"Edwards","year":"2001","journal-title":"J Gastroenterol Hepatol."},{"key":"2022111812273453100_CIT0009","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/j.1572-0241.2005.00256.x","article-title":"Narcotic use in patients with Crohn\u2019s disease","volume":"100","author":"Cross","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0010","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/00365521.2012.743584","article-title":"Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics","volume":"48","author":"Haapam\u00e4ki","year":"2013","journal-title":"Scand J Gastroenterol."},{"key":"2022111812273453100_CIT0011","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1097\/MIB.0000000000000194","article-title":"Narcotic use and misuse in Crohn\u2019s disease","volume":"20","author":"Crocker","year":"2014","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0012","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ibd.21806","article-title":"Narcotic use for inflammatory bowel disease and risk factors during hospitalization","volume":"18","author":"Long","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0013","first-page":"1030","article-title":"The impact of opioid epidemic trends on hospitalised inflammatory bowel disease patients","volume":"12","author":"Cohen-Mekelburg","year":"2018","journal-title":"J Crohns Colitis."},{"key":"2022111812273453100_CIT0014","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/ibd\/izy222","article-title":"Starting young: trends in opioid therapy among US adolescents and young adults with inflammatory bowel disease in the Truven MarketScan database between 2007 and 2015","volume":"24","author":"Wren","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/apt.15023","article-title":"Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids","volume":"49","author":"Noureldin","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2022111812273453100_CIT0016","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s00384-020-03691-y","article-title":"One-year risk of opioid use disorder after index hospitalization for inflammatory bowel disease","volume":"35","author":"Reja","year":"2020","journal-title":"Int J Colorectal Dis."},{"key":"2022111812273453100_CIT0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4292\/wjgpt.v10.i1.22","article-title":"Opioid use and misuse in ulcerative colitis","volume":"10","author":"Chitnavis","year":"2019","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"2022111812273453100_CIT0018","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ibd.20847","article-title":"Clinical features and outcome of patients with inflammatory bowel disease who use narcotics: a case-control study","volume":"15","author":"Hanson","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0019","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004836-198806000-00010","article-title":"Narcotic dependence in inflammatory bowel disease","volume":"10","author":"Kaplan","year":"1988","journal-title":"J Clin Gastroenterol."},{"key":"2022111812273453100_CIT0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/1319-3767.133020","article-title":"Opioid use is associated with decreased quality of life in patients with Crohn\u2019s disease","volume":"20","author":"Sanford","year":"2014","journal-title":"Saudi J Gastroenterol."},{"key":"2022111812273453100_CIT0021","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s10620-019-05906-x","article-title":"Pain in inflammatory bowel disease is not improved during hospitalization: the impact of opioids on pain and healthcare utilization","volume":"65","author":"Berry","year":"2020","journal-title":"Dig Dis Sci."},{"key":"2022111812273453100_CIT0022","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s10620-019-05968-x","article-title":"Opioid analgesics do not improve abdominal pain or quality of life in Crohn\u2019s disease","volume":"65","author":"Coates","year":"2020","journal-title":"Dig Dis Sci."},{"key":"2022111812273453100_CIT0023","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/ibd\/izy040","article-title":"The association between sustained poor quality of life and future opioid use in inflammatory bowel disease","volume":"24","author":"Anderson","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0024","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.cgh.2019.12.024","article-title":"Exposure to intravenous opioids is associated with future exposure to opioids in hospitalized patients with inflammatory bowel diseases","volume":"18","author":"Dalal","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812273453100_CIT0025","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/MIB.0000000000001087","article-title":"Predictors of chronic opioid use in newly diagnosed Crohn\u2019s disease","volume":"23","author":"Pauly","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0026","doi-asserted-by":"crossref","first-page":"e0182900","DOI":"10.1371\/journal.pone.0182900","article-title":"Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease","volume":"12","author":"Micic","year":"2017","journal-title":"PLoS One."},{"key":"2022111812273453100_CIT0027","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1097\/MIB.0000000000000763","article-title":"Demographic and clinical predictors of high healthcare use in patients with inflammatory bowel disease","volume":"22","author":"Click","year":"2016","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0028","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/ajg.2012.343","article-title":"Hospital readmissions in patients with inflammatory bowel disease","volume":"108","author":"Hazratjee","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0029","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2022111812273453100_CIT0030","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics."},{"key":"2022111812273453100_CIT0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pan.2019.11.004","article-title":"Opioid use disorder in admissions for acute exacerbations of chronic pancreatitis and 30-day readmission risk: a nationwide matched analysis","volume":"20","author":"Charilaou","year":"2020","journal-title":"Pancreatology."},{"key":"2022111812273453100_CIT0032","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cgh.2016.09.012","article-title":"Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases","volume":"15","author":"Limsrivilai","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812273453100_CIT0033","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/ibd\/izz100","article-title":"Opioid use is associated with higher health care costs and emergency encounters in inflammatory bowel disease","volume":"25","author":"Alley","year":"2019","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izz104","article-title":"The cost of inflammatory bowel disease: an initiative from the Crohn\u2019s & Colitis Foundation","volume":"26","author":"Park","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/08897077.2012.735216","article-title":"Topical review on the abuse and misuse potential of tramadol and tilidine in Germany","volume":"34","author":"Radbruch","year":"2013","journal-title":"Subst Abus."},{"key":"2022111812273453100_CIT0036","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2017.10.022","article-title":"Increasing prescription of opiates and mortality in patients with inflammatory bowel diseases in England","volume":"16","author":"Burr","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2022111812273453100_CIT0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.diabres.2008.02.011","article-title":"Cardiovascular events and insulin therapy: a retrospective cohort analysis","volume":"81","author":"Engel-Nitz","year":"2008","journal-title":"Diabetes Res Clin Pract."},{"key":"2022111812273453100_CIT0038","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol."},{"key":"2022111812273453100_CIT0039","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/MIB.0000000000001084","article-title":"Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011","volume":"23","author":"Narula","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2022111812273453100_CIT0040","first-page":"970","article-title":"Using the CDC guideline and tools for opioid prescribing in patients with chronic pain","volume":"93","author":"Dowell","year":"2016","journal-title":"Am Fam Physician."},{"key":"2022111812273453100_CIT0041","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrgastro.2017.141","article-title":"Opioid misuse in gastroenterology and non-opioid management of abdominal pain","volume":"15","author":"Szigethy","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"2022111812273453100_CIT0042","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jpain.2018.10.009","article-title":"Influence of abuse history on concurrent benzodiazepine and opioid use in chronic pain patients","volume":"20","author":"Pierce","year":"2019","journal-title":"J Pain."},{"key":"2022111812273453100_CIT0043","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/ADM.0000000000000499","article-title":"Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder","volume":"13","author":"Moreno","year":"2019","journal-title":"J Addict Med."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otab021\/37064453\/otab021.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/3\/2\/otab021\/47117976\/otab021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/3\/2\/otab021\/47117976\/otab021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T12:28:06Z","timestamp":1668774486000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otab021\/6226227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otab021","relation":{},"ISSN":["2631-827X"],"issn-type":[{"value":"2631-827X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2021,4,1]]},"article-number":"otab021"}}